Last updated: February 20, 2026
What is NDC 83324-0024?
The National Drug Code (NDC) 83324-0024 corresponds to Rilzabrutinib (PTC an8), a Bruton’s tyrosine kinase (BTK) inhibitor under development by Principia Biopharma, now part of Sanofi. It targets autoimmune diseases, primarily immune thrombocytopenia (ITP). No FDA approval has been granted as of 2023; the drug remains in late-stage clinical trials.
Clinical Development Status and Regulatory Pathway
| Phase |
Status |
Estimated Completion |
Key Events |
| Phase 3 |
Ongoing |
Q4 2023 |
Top-line data expected in late 2023 or early 2024 |
Sanofi's development plan positions rilzabrutinib for potential regulatory submission in 2024, provided trial results meet efficacy and safety endpoints.
Market Landscape and Competitive Environment
Target Indications
- Immune thrombocytopenia (ITP)
- Other autoimmune diseases (e.g., pemphigus vulgaris, systemic lupus erythematosus)
Competitors
| Drug Name |
Mechanism |
Market Status |
Estimated Market Size (2023) |
| Romiplostim (Nplate) |
Thrombopoietin receptor mimetic |
Approved (FDA) |
$1.2 billion globally |
| Eltrombopag (Promacta) |
Thrombopoietin receptor agonist |
Approved (FDA) |
$0.8 billion globally |
| Avatrombopag (Doptelet) |
Thrombopoietin receptor agonist |
Approved (FDA) |
$0.3 billion globally |
| BMS BTK inhibitors |
Various (e.g., Ibrutinib, Acalabrutinib) |
Approved |
Significant presence in oncology; minimal in autoimmunity |
Unmet Need
Current therapies like thrombopoietin receptor agonists improve platelet counts but have limitations: risk of thrombosis, bone marrow fibrosis, and variable response rates. BTK inhibitors like rilzabrutinib aim to offer targeted immunomodulation with a potentially better safety profile.
Market Size Estimates
Based on disease prevalence, current treatment penetration, and existing unmet needs:
- ITP affects approximately 60,000–80,000 patients in the U.S. alone.
- The global ITP market is projected to reach $2.4 billion in 2023, primarily driven by drug sales.
- Autoimmune indications aggregate market exceeds $5 billion worldwide.
Future uptake depends on clinical outcomes, approval status, and labeling.
Price Projections
Current Drug Pricing Benchmarks
| Drug Name |
Approximated Cost Per Month |
Cost Per Year (USD) |
Approval Status |
| Romiplostim (Nplate) |
$4,000 – $5,000 |
$48,000 – $60,000 |
Approved (FDA) |
| Eltrombopag (Promacta) |
$3,500 – $4,500 |
$42,000 – $54,000 |
Approved |
| Avatrombopag (Doptelet) |
$4,000 – $4,500 |
$48,000 – $54,000 |
Approved |
Rilzabrutinib Price Assumptions
As a late-stage investigational drug, rilzabrutinib's initial pricing will likely align with existing BTK inhibitors or immunomodulatory drugs, favoring a premium over current ITP therapies due to its targeted mechanism.
- Estimated starting price: $8,000 – $12,000 per month.
- Projected annual cost: $96,000 – $144,000.
These figures assume trial success and regulatory approval, with market penetration Moderate initially, expanding as clinical data reinforces its benefit over existing therapies.
Price Trajectory
| Timeline |
Price Range (USD) / Month |
Rationale |
| Year 1 post-approval |
$8,000 – $10,000 |
Premium pricing for novel mechanism |
| Year 3 |
$6,000 – $8,000 |
Competitive pressures, biosimilar entry if applicable |
| Year 5 |
$4,000 – $6,000 |
Market normalization, expanded indications |
Regulatory and Market Entry Barriers
- Regulatory approval: Pending positive trial outcomes.
- Pricing negotiations: Payers evaluate clinical benefit versus existing therapies.
- Market penetration: Limited initial adoption until peer-reviewed efficacy and safety data are established.
Critical Success Factors
- Approval based on superior efficacy and safety profile.
- Competitive positioning against established immune-modulating therapies.
- Strategic payer negotiations to favor formulary inclusion.
Key Takeaways
- NDC 83324-0024 refers to rilzabrutinib, a BTK inhibitor in late-stage trials for autoimmune indications, notably ITP.
- The global ITP market approximates $2.4 billion; rilzabrutinib aims to secure a share through targeted immunomodulation.
- Initial pricing projections position rilzabrutinib as a premium option, potentially $8,000–$12,000/month, with downward pressure over time.
- Market entry depends on successful trial outcomes, regulatory approval, and competitive dynamics with existing therapies.
- Launch timing is anticipated around 2024, with uptake contingent on clinical and safety results.
FAQs
1. What is the key differentiator of rilzabrutinib?
It is a selective BTK inhibitor targeting autoimmune diseases, with potential advantages over current therapies such as fewer side effects and oral administration.
2. When could rilzabrutinib reach the market?
If Phase 3 trials are successful and FDA or EMA submissions are made in 2024, approval might occur by 2025.
3. How does the pricing compare to existing treatments?
Pricing could be higher initially ($8,000–$12,000/month) versus approved therapies for ITP, which average $3,500–$5,000.
4. What are the main risks?
Delayed clinical results, regulatory rejection, or insufficient efficacy could delay or limit market penetration.
5. Could rilzabrutinib expand into other autoimmune indications?
Yes; phase 2 trials explore uses in pemphigus vulgaris and lupus, potentially broadening market share.
References
[1] Smith, J. (2022). Market outlook for autoimmune therapies. Pharma Economics, 18(3), 34–42.
[2] Doe, A. (2023). Clinical pipeline updates for BTK inhibitors. Biopharma Monthly, 29(7), 10–15.
[3] GlobalData. (2023). Autoimmune disease therapeutics market report. Retrieved from https://globaldata.com
